Cord Blood

Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.

Americord Seeks Up To $6M To Fuel Its Rapidly Expanding Cord Blood Business

February 6, 2018 By Cade Hildreth, Founder & President Leave a Comment

Americord Registry LLC Seeks Up To $6 Million In Funding To Fuel Its Rapidly Expanding Business

NEW YORK, Feb. 2, 2018 — Americord Registry LLC is seeking up to $6 million in funding to fuel its rapidly expanding business. Ranked for the past three years as one of the fastest growing private companies in the United States, Americord intends to use the additional funds to continue its history of innovation through the development and promotion of new stem cell collection technology and innovative new stem cell therapies. [Read more…]

Cordlife Becomes Cord Blood Market Leader in Hong Kong with Acquisition of HealthBaby

January 3, 2018 By Cade Hildreth, Founder & President Leave a Comment

Continues trend of cord blood industry consolidation on a global basis

SINGAPORE, 3 January 2018 – Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”) has signed a sale and purchase agreement to acquire full control of HealthBaby Biotech (Hong Kong) Co., Limited (“HealthBaby Hong Kong”), in a move that will expand its presence in the private cord blood banking industry in Hong Kong and Macau. [Read more…]

EONE-DIAGNOMICS Genome Center Partners with Cordlife to Expand Into East Asian Market

December 19, 2017 By Cade Hildreth, Founder & President Leave a Comment

SEOUL, South Korea, Dec. 18, 2017 — Eone-Diagnomics Genome Center (EDGC), a Korean genetic analysis company, said today it will expand its business into East Asian market with Asia’s largest network of cord blood and cord lining banking service provider “Cordlife” as the company aims to expand its geographical presence in Asian genome market.

The company expects Cordlife, who operates its cord blood and cord lining banking business in numbers of Asian countries as a market leader, to be the best possible partner while the company is taking bold steps to grow in both scale and scope in Asian market.

EDGC will initially begin to service its Non-Invasive Prenatal Test (NIPT), named “Gen Screen,” to both the Philippines and Indonesia through Cordlife’s sales network within each country.

In particular, Indonesia has the second highest birth rate in the world after China. Making a move into such a country, the company is expected to see a definite steep growth in sales. [Read more…]

Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients

December 12, 2017 By Cade Hildreth, Founder & President Leave a Comment

– Data show rapid and durable engraftment with MGTA-456, an expanded cord blood stem cell product, in all 18 patients with hematologic malignancies across all conditioning regimens tested –
– MGTA-456 achieves clinical benefits of cord blood transplant –
– Clinically validated process to expand the numbers of CD34+ cells by >300 fold in single cord blood units significantly increases probability of identifying better HLA-matched stem cell donors for patients

December 11, 2017, CAMBRIDGE, Mass.–Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today reported Phase 2 clinical data from its MGTA-456 hematopoietic stem cell (HSC) expansion program at the 59^th annual meeting of the American Society of Hematology (ASH) in Atlanta, Ga. MGTA-456 is a single umbilical cord blood unit expanded with an aryl hydrocarbon receptor (AHR) antagonist. It is currently being studied in adult and pediatric patients with hematologic malignancies.

[Read more…]

Cord Blood vs. Bone Marrow vs. Peripheral Blood

December 6, 2017 By Cade Hildreth, Founder & President Leave a Comment

To understand the benefits of cord blood vs. bone marrow vs. peripheral blood, it is important to understand the use of each within HSCT. Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells derived from bone marrow, peripheral blood, or umbilical cord blood. It is performed for patients with cancers of the blood or bone marrow, such as leukemia and multiple myeloma, making it the leading type of cell therapy performed worldwide. [Read more…]